a public good project by the
Synthesis
Company
of California

© 2026

Gary E. Gallick | doi.page

0 works0 citations0 h-index

Gary E. Gallick

Publications by Year

Research Areas

Prostate Cancer Treatment and Research, Colorectal Cancer Treatments and Studies, Bone health and treatments, PI3K/AKT/mTOR signaling in cancer, Pancreatic and Hepatic Oncology Research

Most-Cited Works

→ Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer(2009)861 cited
→ BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571(2002)662 cited
→ Acquisition of Epithelial-Mesenchymal Transition Phenotype of Gemcitabine-Resistant Pancreatic Cancer Cells Is Linked with Activation of the Notch Signaling Pathway(2009)619 cited
→ Development and Characterization of Gemcitabine-Resistant Pancreatic Tumor Cells(2007)432 cited
→ Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer.(1993)397 cited
→ Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice(2009)381 cited

→ HIF-1α, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas(2005)

371 cited

→ EGCG, a major component of green tea, inhibits tumour growth by inhibiting VEGF induction in human colon carcinoma cells(2001)328 cited

→ A ROR1–HER3–lncRNA signalling axis modulates the Hippo–YAP pathway to regulate bone metastasis(2017)317 cited

→ ALDH Activity Selectively Defines an Enhanced Tumor-Initiating Cell Population Relative to CD133 Expression in Human Pancreatic Adenocarcinoma(2011)299 cited